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Abstract
RNA-binding proteins may regulate every aspect of RNA metabolism, including pre-mRNA splicing, mRNA
trafficking, stability and translation of many genes. The dynamic association of these proteins with RNA defines the
lifetime, cellular localization, processing and the rate at which a specific mRNA is translated. One of the pathways
involved in regulating of mRNA stability is mediated by adenylate uridylate-rich element (ARE) binding proteins.
These proteins are involved in processes of apoptosis, tumorigenesis and development. Out of many ARE-binding
proteins, two of them AUF1 and HuR were studied most extensively and reported to regulate the mRNA stability in
vivo. Our previously published data demonstrate that both proteins are involved in thyroid carcinogenesis. Several
other reports postulate that mRNA binding proteins may participate in thyroid hormone actions. However, until
now, exacts mechanisms and the possible role of post-transcriptional regulation and especially the role of AUF1
and HuR in those processes remain not fully understood. In this study we shortly review the possible function of
both proteins in relation to development and various physiological and pathophysiological processes, including
thyroid function and disorders.
Introduction
Cytoplasmic stability of eukaryotic mRNA is a substan-
tially important check point in the control for gene
expression. During differentiation of the cell some
mRNAs are expressed stronger and some others are
degraded or down regulated. Such a post-transcriptional
gene-inactivation (gene silencing) occurs through altera-
tions in translational efficiency and in mRNA stability.
Stability of mRNA is mainly controlled by RNA interfer-
ence processes (e.g. siRNA, microRNA) and RNA bind-
ing proteins, which act to selectively degrade or stabilize
mRNAs. In mammals, a common feature of many
unstable mRNAs is the presence of an Adenylate-Uridy-
late-rich element (ARE) within the 3’-untranslated
region (3’-UTR) [1-3]. This ARE in the 3’-untranslated
region is a part of the regulation system, which is
responsible for the mRNA degradation or stabilisation
and is linked to an interaction with ARE binding pro-
teins. Out of many ARE-binding proteins studied, two
of them AUF1 and HuR were investigated most exten-
sively and demonstrated to affect the mRNA stability in
vivo. AUF1 (A+U rich RNA-binding factor 1, heteroge-
neous nuclear ribonucleoprotein D) is expressed as a
family of four proteins designated by their molecular
masses as p37, p40, p42 and p45 arising from a single
transcript. HuR (human antigen R) is a ubiquitously
expressed member of the embryonic lethal abnormal
vision (ELAV) family [4]. Although there are some
examples demonstrating stabilizing function of AUF1, it
is generally related to degradation of target mRNAs
while HuR is known to promote stabilization of several
transcripts by enhancing their stability, altering their
translation, or performing both functions [5-7]. Both
proteins are mainly expressed in nucleus but their func-
tion is related with cytoplasmic localisation. Predomi-
nantly nuclear AUF1 and HuR shuttle between the
nucleus and cytoplasm via nucleocytoplasmic shuttling
sequences called DNS and HNS, respectively. In case of
AUF1, its nuclear import is mediated by transportin-1
[8,9]. The mechanisms of AUF1 and HuR are believed
to be mediated by binding-competition to target
mRNAs. It is postulated that AUF1 and HuR could
functionally act with target mRNAs both within the
nucleus and in the cytoplasm [10]. It suggests that pre-
cise mechanism of antagonising and/or cooperative
actions of AUF1 and HuR is not entirely understood.
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Both proteins do not posses any enzymatic activity, but
were identified with ARE-mRNA-protein-ligand com-
plexes. Previous reports identified the ubiquitin-conju-
gating enzyme E2I and three RNA binding proteins:
NESP-1, NSAP-1 and IMP-2, as AUF1 interacting pro-
teins. Importantly, NSEP-1 revealed an endoribonuclease
activity, providing possible explanation for AUF1-
mediated poly(A) shortening [11]. With regard to HuR,
affinity chromatography and co-immunoprecipitation
experiments identified four protein ligands SETa, SETb,
pp32 and acidic protein rich in leucine (APRIL) [12].
First three had been previously characterised as inhibi-
tors of protein phosphatase 2A (PP2A) regulating its
ability to convert between holoenzyme forms upon sti-
mulation [13,14]. PP2A is known serine/threonine phos-
phatase participating in diverse cellular processes such
as proliferation, cell cycle, DNA replication, develop-
ment and morphogenesis [15]. Recently, HuR and AUF1
were identified as components of the RNA-induced
silencing complex (RISC). In this study HuR employed
AUF1 as cofactor to promote p16 mRNA decay [16].
ARE-elements are found in many mRNAs encoding
proteins related to normal and neoplastic cell growth
and must be considered as a crucial target element in
mammalian cells. The human genome project revealed
that many mRNAs encoding proto-oncogenes (i.e. c-
myc, c-jun, c-fos), growth factors such (i.e. EGF, VEGF),
cytokines (i.e. TNFa) and cell cycle regulators (i.e. cyclin
A, B1, D1, p21, p27) contain ARE-motifs [17,18]. Analy-
sis of thyroid related genes revealed that many of them
contain these motifs and may be regulated at the post-
transcriptional level. These include mRNAs related with
thyroid function (pendrin, NIS, MCT8, peroxiredoxins,
TPO, dual oxidase 1), regulation of thyroid function
(TSHR), response to thyroid hormones (selenoprotein P,
THR alpha and beta, THR associated protein 6, D1),
thyroid development (Nkx2-1, PAX8, HHEX, EYA1,
Hox-A3, Hox-A5, PAX9) and thyroid pathology (thyroid
adenoma associated protein, papillary thyroid carcinoma
encoded protein, thyroid cancer protein) (Table 1).
However whether these mRNAs may serve as potential
targets for AUF1 and HuR is still unclear. It is worth to
note that both proteins may also interact with some
mRNAs by employing non-canonical ARE-sites [19,20].
Developmental expression of AUF1 and HuR
Both proteins are synchronous, but differential
expressed during murine development. It had been
demonstrated that there is no major translation control
of AUF1 and HuR production, but their expression var-
ies noticeably within tissues and at differential develop-
mental stages. The tissue distribution of both proteins
demonstrated that yolk-sack and fetal liver possessed
very weak levels of AUF1 and HuR, contrary to strong
expression in tail, limb bud, brain and heart between
E13.5 and E16.5. Adult spleen, thymus, testis and intes-
tine were very abundant in AUF1 and HuR, contrary to
brain, liver, heart, kidneys, muscle, lungs and stomach,
demonstrating low or no expression of both proteins.
AUF1 and HuR revealed a coincident spatio-temporal
tissue distribution from 10-somite stage to late embryo-
genesis [21,22].
The data coming from human tissues revealed that
AUF1 and HuR are also strictly involved in liver de-dif-
ferentiation, development and progression of hepatocel-
lular carcinoma. Those processes are tightly regulated
by MAT1A (methionine adenosyltransferase 1A)- and
MAT2A (methionine adenosyltransferase 2A. Both
enzymes control the levels of S-adenosylmethionine
(SAM), the key regulator of hepatocytes proliferation
and differentiation. MAT1A is expressed in adult liver,
whereas MAT2A is detected extrahepatic and is related
with liver proliferation. The analysis of those expression
patterns revealed that AUF1 and HuR are crucial post-
transcriptional regulators of MAT1A and MAT2A
mRNA stability. The authors demonstrated that AUF1
and HuR levels were upregulated in a time-dependent
manner during liver de-dedifferentiation and the func-
tion of HuR is regulated by its methylation status. The
interaction of HuR with MAT2A mRNA in the presence
of SAM led unexpectedly to MAT2A mRNA decay,
whereas its absence promoted HuR-mediated accumula-
tion of MAT2A mRNA. It is worth to note that addition
of SAM reduced the AUF1 interaction with this mRNA.
The analysis of rat liver development revealed that there
is a switch in the expression from MAT2A to MAT1A
during embryogenesis. Proliferating liver express
increased levels of SAM-methylated HuR which leads to
decreased MAT2A mRNA expression and elevated
levels of MAT1A mRNA. Furthermore, increased levels
of AUF1 and HuR, and decreased levels of methylated-
HuR were detected in hepatocellular carcinoma tissues.
Normal liver tissues express very low levels of AUF1
and HuR, and high levels of methylated-HuR [23].
In vivo data on AUF1 and HuR knock-out mice mod-
els demonstrated that both proteins may play an impor-
tant role in the development. Investigations of AUF1 -/-
mice revealed symptoms which share similarity with
human atopic dermatitis such as pruritus, chronic der-
matitis, cutaneous atopy, xerosis, elevated serum IgE
levels and staphylococcal skin infection [24]. Cunning-
ham et al. observed the presence of thyroid disorders in
patients suffering from dermatitis herpetiformis. How-
ever the association between the clinical or serological
thyroid abnormalities and skin disease could not be
explained [25]. Recently different skin findings and
accompanying dermatoses could be detected in patients
with thyroid diseases. The presence of each dermatosis,
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chronic urticaria, vitiligo and pruritus were found to be
significantly higher in the patient group with thyroid
disorders than in the control group. Autoimmune-
hyperthyroidism patients demonstrated significantly
higher incidence of vitiligo and diffuse alopecia, while
vitiligo alone was found to be significantly higher in
autoimmune hypothyroidism patients than in the con-
trol group [26]. It had been demonstrated that AUF1-
deficient mice revealed abnormal stabilisation of TNFa
and IL-1b mRNAs. Such an excessive proinflammatory
cytokines production resulted in endotoxic shock, loss
of renal and liver function and in end effect caused
increased mortality [27]. In studies by Sadri et al. AUF1-
deficiency led to disturbance in mature splenic B cell
populations and impaired humoral immune responses.
The authors observed decreased number of splenic lym-
phocytes, increased presentation of immature marginal
zone lymphocytes and reduced number of mature folli-
cular B lymphocytes [28].
More severe abnormalities were observed in HuR -/-
animals. It had been demonstrated that HuR was crucial
for midgestational embryonic development. HuR expres-
sion increased in murine placenta between E12.5 and
E13.5. Immunohistochemical analysis revealed its pre-
sence in both embryonic and extraembryonic layers;
however HuR nucleo-cytoplasmic localisation varied
between maternal and fetal sides. It was dominantly
nuclear in maternal decidua cells and embryo-derived
trophoblasts giant cells and spongiotrophoblasts. Con-
trary, labyrinth-trophoblasts showed nuclear and strong
cytoplasmic staining. The presence of HuR in cytoplasm
at this stage was probably related with its function.
Furthermore, the HuR -/- led to midgestational death.
In the absence of HuR the labyrinth branching morpho-
genesis and syncytiotrophoblast differentiation were
impaired and caused not sufficient vascularization,
labyrinthine apoptosis, and in end effect insufficient
nutrient transport and embryos death. Most of the
embryos died between E17.5 and E19.5. They revealed
reduced size of skeleton and limbs and decreased spleen
size. Furthermore, the lungs of HuR -/- mice revealed
additional dysmorphologies, whereas the stomach and
pancreas were properly located. However, whether the
absence of HuR could lead to thyroid abnormalities was
not investigated. It is worth to note that HuR was able
to interact with several transcription factors crucial not
Table 1 ARE-containing mRNAs related to thyroid function, development and disorders. According to AREsite http://
rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi.
ARE-motifs
mRNA AUUUA WTAUUUATW WWWWAUUUAWWWW WWAUUUAWW Others
Selenoproten P 6 1 1 2
MCT8 5
ID2 3 1 1 1 1
Pendrin 6 2 1 2 4
THR alpha 2 1
THR beta 14 1 2
Thyroid adenoma associated protein 18 1 2 6 6
TTF-1 (Nkx2-1) 6 3 2 4 4
TSH-R 2
TPO 3 2
THR associated protein 6 2 1
Papillary thyroid carcinoma encoded protein 10 2 1 3 2
Dual oxidase 1 1
Thyroid cancer protein 5 1 1 2 2
PAX8 3 1 2 3
NIS 1
D1 3
Homebox protein HEX (HHEX) 2
Eyes absent homolog EYA1 5 2 1
Homebox protein Hox-A3 7 1 1 1 3
Homebox protein Hox-A5 1 1 1
PAX9 4 1 3
Peroxiredoxin 6 (PRDX6) 2
Peroxiredoxin 3 (PRDX3) 1
Peroxiredoxin 4 (PRDX4) 1
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only for proper morphogenesis, patterning and specifica-
tion, but also for thyroid development such as Hox-A5
[29].The absence of Hox-A5 is related to disorganized
follicle formation; decreased TPO; Nkx2.1, Titf2, altered
Pax8 gene expression, but normal serum T4 level. As
demonstrated in Table 1, these mRNAs bear ARE-
sequences and are crucial for thyroid development
(Table 2). However, whether their mRNA stability is
regulated in ARE-dependent manner, especially in parti-
cipation of AUF1 and HuR, is not clear.
Thyroid hormone and TSH-mRNA
There is still a growing body of evidence that actions of
thyroid hormone (TH), thyroid function and disorders
may also be regulated at post-transcriptional level by
mRNA binding proteins. Krane at al. demonstrated that
TH is able to regulate the stability of thyroid stimulating
hormone (TSH) subunit mRNA. They showed that half-
life of the TSH beta mRNA from rat pituitary cultures
treated with triiodothyronine (T3) was shorter than that
observed in corresponding controls. Furthermore, TSH
mRNA was destabilized due to the loss of a portion of
the poly(A) tail upon TH treatment [30]. Staton at al.
postulated that such a mechanism is highly conserved
across the species. In addition to previous studies they
observed that simple deadenylation of TSH messenger
body is insufficient to induce its decay [31]. This sug-
gests the triggering of additional mechanism such as
exonuclease digestion and actions of other still not iden-
tified mRNA binding proteins. Recently, Goulart-Silva et
al. demonstrated a rapid effect of T3 on TSHb mRNA
stability. They showed that surgically hypothyroided rats
revealed an increased TSHb transcript poly(A) tail, its
elevated content in ribosomes and enhanced attachment
to cytoskeleton. Furthermore, hypothyroid rats subjected
to acute T3 treatment demonstrated a reduction of
TSHb mRNA poly(A) tail and its weakened recruitment
to ribosomes. Euthyroid rats did not present any
changes in TSHb mRNA stability, but revealed increased
binding of TSHb transcripts to ribosomes [32].
Although exact mechanisms or proteins participating in
mRNA degradation are not fully identified, Leedman et
al. isolated a cytoplasmic trans-acting factor (80-85 kDa)
capable to bind the 3’-UTR of TSHb transcripts.
Furthermore, its binding to TSHb transcripts was posi-
tively regulated by T3 [33]. With regard to AUF1 and
HuR, their actions in regulating the TSHb transcript sta-
bility may be elusive at present, but it is worth to note
that AUF1 function is associated with polysomes [10].
Thyroid hormone and other mRNAs
Murphy et al. observed that growth hormone (GH)
mRNA from TH-depleted rats is less abundant than
euthyroid controls, but its stability is elevated due to the
increased length of poly (A) tail. The authors observed
that modulation of GH poly (A) is related to nucleus
and its length may be regulated due to the interactions
with free ribonucleoproteins. The existence of such a
nuclear mechanism resulting in cytoplasmic stabilisation
of mature GH mRNA raises the question which mRNA
binding proteins may mediate these effects [34]. Recent
studies by Goulart da Silva et al., revealed that TH
acutely increases GH mRNA translation rate and GH
secretion in hypothyroid rats. It had been shown that
soon after T3 administration, increased GH labelling
was observed in the perinuclear region of somatotrophs
and that these events coincided with cytoskeleton rear-
rangements. Indeed, the authors identified GH mRNA
in complexes with F-actin, which provided additional
protection for GH mRNA transcripts. Furthermore, as
the authors postulated, insufficient GH synthesis in
hypothyroid specimens resulted not only from reduced
GH transcription rate but also decreased GH mRNA
half-life [35]. This novel finding directing GH mRNA
soon after T3 administration to polysomes is related
with TH nongenomic actions. However, whether addi-
tional molecular mechanisms are involved in those pro-
cesses, remains an open question.
With regard to other mRNAs, the effects of TH on
cardiovascular development may also be mediated by
actions of mRNA-binding proteins. Minamisawa et al.
demonstrated that stability of sarcolipin mRNA, an
atrium-specific sarcoplasmic reticulum protein, is
affected by thyroid hormone actions. Analysis of atria
obtained from hyperthyroidism-induced and T3-treated
neonatal rat atrial myocytes revealed accelerated decay
Table 2 Thyroid developmental markers containing ARE-
sequences and phenotypes studied on double knock-out




Pax8 -/- Regression of thyroid primordium at E11.5
Thyroid precursor cells disappear at E12
No follicles, no Tg, no TPO;
thyroids exclusively consist of C-cells (Ttif1-positive)
Pax9 -/- Lack of ultimobranchial body formation
Ttif1/Nkx2.1 -/- Thyroid precursor cells disappear at E10.5-11.5;
Mice lack C-cells and thyroid follicular cells
Hhex -/- Thyroid anlage present at E9;
Absence of thyroid primordium at E10
Eya1 -/- lack of fusion between ultimobranchial bodies and
thyroid lobes; thyroid hypoplasia; severe reduction in
number of C-cells and follicular cells;
Hoxa3 -/- Thyroid hypoplasia; persistent ultimobranchial bodies
with C-cells
Hoxa5 -/- Disorganized follicle formation; decreased TPO; Nkx2.1,
Titf2, Pax8 gene expression altered, but normal serum
T4 level
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of sarcolipin mRNA. The hyperthyroid mice revealed
cardiac hypertrophy and sinus tachycardia. Contrary,
hypothyroidism did not result in any changes of cardiac
morphology and sarcolipin mRNA stability [36]. It had
been demonstrated that myocardial relaxation and asso-
ciated cardiac hypertrophy and heart failure may be
related with AUF1-mediated decrease of sarco(endo)
plasmic reticulum calcium ATPase 2a (SERCA2a)
mRNA stability. In those studies AUF1 was identified as
a critical factor of these events. Interaction of AUF1
with SERCA2a 3’ UTR was identified predominantly in
nucleus, suggesting that AUF1-mediated decay of SER-
CA2a mRNA starts within the nucleus and further con-
tinues during shuttling to the cytoplasm [37].
The further role of AUF1 was shown in studies con-
cerning the mRNA stability of Kv4 channels. Expression
of cardiac myocyte Kv4 channels is down-regulated in
hypertrophy and leads to decrease in the transient out-
ward current. Studies in vitro demonstrated that
employment of angiotensin II may recapitulate these
effects and is accompanied by up-regulation of AUF1,
which in turn binds and destabilises Kv4 mRNA [38].
Studies on cultured rat brown adipocytes revealed that
at higher doses T3 inhibited deiodinase II (D2) activity.
Similar effects were induced after administration of
triiodothyroacetic acid (Triac) , a natural thermogenic
compound in brown adipocytes. Low concentrations of
Triac increased D2 activity, while its higher doses inhib-
ited D2 activity. The authors postulate that D2-inhibiton
by employing high T3 doses may exist as a regulatory
pathway in which D2 triggers down-regulation of T3,
against its excess. D2 activity is inhibited in hyperthyr-
oidism, and decreases further after chronic cold exposi-
tion. This suggests that high T3 concentrations in
brown adipocytes switch off the mechanisms of T3-pro-
duction via D2. Furthermore, the inhibition of D2 activ-
ity was found on post-transcriptional level and was
related with proteasome actions. It had been demon-
strated that addition of ubiquitin led to D2 inactivation
whereas protein deubiquitintating enzyme-1 reversed
ubiquitin-mediated inactivation and prolonged D2 half-
life. Furthermore, D2 was also stabilised by employing
of proteasome inhibitor. Deubiquitintating enzyme-1
was found noticeably increased in brown adipocyte tis-
sue upon cold exposure and was associated with
increased D2 stability.
Although there is no direct evidence that T3 regulates
proteasome activity or increase D2 decay, the authors
could demonstrate that T3 at high doses and THR beta
participate in regulation of D2 mRNA stability, T3 by
shortening D2 half-life and induction of D2-degradation,
and THR beta by stabilisation of D2 activity [39-43].
TH is also implicated in regulation of neuroserpin
mRNA stability. Neuroserpin is a serine protease
inhibitor of the serpin family playing an important role
in neural development and adult neural function. Neu-
roserpin dysfunction is related with different neurode-
generative diseases. It has been shown that its 3’UTR
contains ARE motifs and interacts with HuD protein,
belonging as HuR to the ELAV family. HuD is able to
bind neuroserpin mRNA and its overexpression was
associated with increased mRNA stability. Employment
of T3 led to decreased half-life of neuroserpin, probably
due to the HuD repression. The authors also suggest
the involvement of other mRNA binding proteins [44].
In studies with retinoic acid receptors (RAR) it has
been demonstrated that administration of TH led to
enhanced mRNA levels of RARb, decreased RXRg and
had no influence on RXRa. In addition to positive tran-
scriptional regulation of RARb by TH, investigations
concerning the regulation of RXRg, revealed that TH
regulate its mRNA stability post-transcriptional [45]. As
RXRg mRNA bears the ARE-motifs, it is a possible part-
ner for ARE-binding proteins.
Trace elements
Recent studies revealed that also trace elements such as
selenium, calcium or iron may regulate the mRNA sta-
bility of proteins related to their transport or metabo-
lism [46-49]. Studies in vitro revealed potential roles of
calcium and phosphate in AUF1-mediated mRNA stabi-
lity of parathyroid hormone (PTH). PTH mRNA levels
are post-transcriptional increased by hypocalcemia and
decreased by hypophosphatemia. AUF1 was identified as
a critical factor protecting and stabilizing PTH tran-
scripts [50]. With regard to thyroid function, it has been
demonstrated that iodide and selenium may affect the
stability of thyroid-related mRNAs. Bermano et al.
showed that selenium depletion decreased the stability
of cytosolic glutathione peroxidase mRNA. Furthermore,
the incorporation of Se-cysteine at specific UGA codons
in the selenoenzyme mRNAs was dependent on the pre-
sence of stem-loop structures in the 3’-UTRs of these
mRNAs. It was demonstrated for selenoenzymes type I
(D1) and type III deiodinases (D3) revealing that their
translation efficiency was dependent on the structure or
sequence of the 3’- UTR [51]. The existence of Se-
dependent post-transcriptional mechanisms regulating
D1 mRNA stability was also reported in study by Riese
et al., suggesting regulation in a sex and tissue specific
manner [52]. Although involvement of AUF1 and/or
HuR in Se-regulated mRNA stability may be elusive at
present, its worth to note that 3’- UTR of D1 bears
ARE-motifs and may be regulated in ARE-dependent
fashion.
Recent studies demonstrated that acute iodide admin-
istration decreased the mRNA stability of sodium-iodide
symporter (NIS). The authors observed that NIS
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transcripts and the length of NIS poly (A) tail were sig-
nificantly reduced during all periods of iodide treatment.
The authors postulate that this mechanism involves the
interaction of trace elements such as iodide with pro-
teins bound to untranslated regions of mRNAs. This
novel mechanism provide a new insight by which iodide
may exert its autoregulatory function on thyroid gland
[53]. However whether iodide or other trace elements
may bind and regulate the activity of exosome and/or
proteasome components in ARE-dependent manner
remains to be identified.
Thyroid cancer
Current data from our group revealed that AUF1 and
HuR may be involved in thyroid pathology by regulating
the stability of several factors related to cell cycle and
proliferation. We demonstrated that thyroid cancer tis-
sues expressed AUF1 significantly stronger than benign
tissues. Furthermore, AUF1-knock-down in follicular
thyroid carcinoma cells FTC-133 led to decreased prolif-
eration rates accompanied by increased expression of
cell cycle inhibitors and down-regulation of cell cycle
promoters. The analysis of AUF1-depleted clones
revealed that in addition to AUF1-down-regulation, all
clones demonstrated also decreased HuR levels [54].
However exact mechanisms, thyroid-specific partners
for AUF1 and HuR, the influence of AUF1 and HuR on
thyroid specific functions and genes, the role of mRNA
stability in thyroid carcinogenesis are still not fully
understood. Recent studies by Braun et al. identified
altered microRNA signatures as potent post-transcrip-
tional markers for undifferentiated thyroid carcinoma
that promote its de-/transdifferentiation and invasion
[55].
Our previously published data revealed that expression
of several tumor suppressor genes (TSG) and tumor
promoting factors, may serve as novel biomarkers for
thyroid carcinoma. We demonstrated that down-regula-
tion of CD9, CD82 and RKIP may reflect an increased
in vivo metastatic potential of thyroid cancer cells
[56,57]. Inversely, increased expression of S100A4 and
ENO1 was correlated with increased proliferation and
metastatic potential of thyroid carcinoma [58]. Investiga-
tions performed on AUF1-depleted thyroid cancer cell
lines revealed a cross-link between AUF1 and CD9,
CD82, S100A4 and ENO1. We demonstrated that AUF1
knock-down led to increased expression of two tumor
suppressor genes CD9 and CD82. Subsequently,
decreased expression of tumor promoting S100A4,
GAPDH and ENO1 was observed (Fig. 1).
It had been demonstrated that retinoic acid (RA) treat-
ment induced beneficial effects in therapy of solid can-
cers [59,60] including thyroid carcinomas [61-63]. Cell
culture experiments performed on thyroid carcinoma cell
lines revealed that RA treatment affects thyroid-specific
functions, cell-cell or cell-matrix interaction, differentia-
tion markers, growth, and tumorigenicity [64]. Adminis-
tration of RA demonstrated an anti-proliferative effect on
the follicular thyroid carcinoma cell lines FTC-133 and
FTC-238. Furthermore, pre-treatment of these cell lines
with RA resulted in decreased in-vitro proliferation rates
and reduced tumor cell growth of xenotransplants [65].
Our published data revealed that RA led to significantly
decreased levels of of glyceraldehyde-3-phpsphate dehy-
drogenase (GAPDH), pyruvate kinase isoenzymes M1/
M2 (PKM1/M2), peptidyl-prolyl cis-trans isomerase A
(PPIA), transketolase (TKT), annexin A2 (ANXA2), glu-
tathione S-transferase P (GSTP1) and peroxiredoxin 2
(PRDX2) as compared to untreated control. Investiga-
tions on thyroid tissues demonstrated that the same pro-
teins were significantly up-regulated in follicular,
papillary and undifferentiated thyroid carcinomas [66]. In
addition to previously published data we found that RA
pre-treatment led to down-regulation of AUF1 and HuR.
Also depletion of ENO1 led to decreased levels of AUF1
and HuR (Fig. 2).
Other types of cancer
Both proteins were reported to be also related with
other malignancies, and like in case of thyroid cancer,
were expressed synchronous. Given that both proteins
bind to common target mRNAs such an expression pat-
tern is partly explainable. In studies on transgenic mice
the overexpression of AUF1 led to development of sar-
comas with strong expression of cyclin D1 [67]. Other
in vivo mice models demonstrated that malignant lung
tissues expressed AUF1 significantly stronger as com-
pared with normal and benign lung tissues. The same
expression pattern was reported for HuR protein [68].
With regard to HuR expression, its increased levels were
demonstrated for malignant tissues of tongue, gingival,
colon, breast, ovary and stomach as compared to corre-
sponding controls [69,70].
It had been shown that approximately 80% of anaplas-
tic lymphoma kinase (ALK)-positive lymphomas express
the fusion protein called nucleophosmin-anaplastic lym-
phoma kinase (NPM-ALK), which constitutively acti-
vates ALK tyrosine kinase and causes abnormal
induction of down-stream signaling resulting in malig-
nant transformation. Studies in vitro revealed that AUF1
was co-localised with NPM-ALK in the same cytoplas-
mic loci. Subsequent hyperphosphorylation of AUF1 in
NPM-ALK expressing cells was also observed. It is
worth to note that AUF1 hyperphosphorylation was
associated with elevated stability of several target
mRNAs encoding proteins crucial for cell proliferation
and cell survival such as c-myc, and cyclin D1, cyclin
A2, cyclin B1, and cyclin D3 [71].
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Overexpression of AUF1 (especially isoforms p37 and
p45) resulted in enhanced translation of internal ribo-
some entry site (IRES) of Hepatitis C virus (HCV),
which is one of the major agents causing a virus-related
hepatitis, liver cirrhosis and hepatocellular carcinoma.
Depletion of AUF1 significantly hampered infection by
HCV [72]. Similar mechanisms were also reported by
depletion of insulin-like growth factor 2 mRNA binding
protein IGF2BP1 [73].
Increased expression of AUF1, heterogeneous nuclear
ribonucleoprotein K (HNRNPK), MutS homolog 2
(MSH2) and grainyhead-like 2 (GRHL2), and subse-
quently elevated activity of human telomerase reverse
transcriptase (hTERT) were detected in human oral
squamous cell carcinoma cells (OSCC) when compared
to normal cells, which do not exhibit hTERT activity.
RNAi mediated knock-down of AUF1, MSH2 and
GRHL2 resulted in decreased proliferation rates and
hTERT promoter activity. Depletion of HNRNPK inhib-
ited only proliferation of the cells without affecting the
hTERT promoter activity [74].
Prostaglandin A2 (PGA2) is an experimental anti-can-
cer agent associated with decreased levels of cyclin D1
and decreased proliferation of cancer cells. It has been
demonstrated that employment of PGA2 induced AUF1
expression and resulted in degradation of cyclin D1
mRNA in non small cell lung cancer (H1299) and breast
carcinoma (MCF-7) cells. The other breast carcinoma
cell line tested MDA-MB-453, bearing a large deletion
in cyclin’s D1 3’UTR, responded with unaltered cyclin
Figure 1 Upper panel: expression of CD82 in thyroid carcinoma cell lines treated with siRNA targeting AUF1. Lower panel: expression of CD9,
CD82, GAPDH, ENO1 and S100A4 in wild type cells FTC-133, FTC-133-EGFP control cells (E19) and FTC-133 transfectants expressing AUF1
targeting shRNAs (A13, A17, A21). Increased levels of tumor suppressors (CD9 and CD82) and subsequent decrease of tumor promoters (ENO1,
GAPDH and S100A4) are visible. Note that 8505C control and AUF1-siRNA cells are CD82 negative. 18S and B-actin served as normalizing
markers.
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D1 mRNA upon PGA2 treatment [75]. In melanoma
cells increased elevated levels of interleukin 10 (IL-10)
resulted in decreased cytosolic AUF1 levels as compared
with normal melanocytes [76].
Non-cancerous actions and disorders
The role and actions of AUF1 and HuR were also
reported in other non-cancerous disorders. AUF1 pro-
teins were identified as novel autoantigens in systemic
lupus erythematosus (SLE) and other associated autoim-
mune rheumatic disorders. Autoantibodies to AUF1
were detected in 33% of SLE patients, 20% of patients
with rheumatioid arthritis, 17% of patients with mixed
connective tissue disorders and below 10% of patients
with other related rheumatic diseases. Healthy controls
were negative for AUF1 autoantibodies [77]. The pre-
sence and the role of HuR autoantibodies are discussed
in non-neuronal tissues [78].
The role of post-transcriptional gene regulation was
also studied in the cells upon low oxygen levels. It has
been demonstrated that in hypoxia conditions, HuR up-
regulates the expression of two major hypoxia-inducible
proteins, VEGF and HIF-1a. Furthermore, HuR also
regulates the levels and/or translation of other ARE-con-
taining mRNAs which encode hypoxia-inducible pro-
teins such as GLUT1, TGF-b, c-myc and p53 [79]. With
regard to p53, HuR is able to bind Mdm2 mRNA, a cri-
tical negative regulator of p53. The authors suggest that
by regulation of p53 levels HuR promotes the survival
of hematopoietic progenitor cells [80]. Until now the
possible role of AUF1 in those processes remains
undiscovered.
Both proteins were also identified as critical mediators
of replicative senescence. It had been shown that reduc-
tion of AUF1 level occurred with replicative senescence
and contributed to stabilization and elevated expression
of ARE-bearing p16 mRNA in senescence-phenotype
cells [81]. Interestingly, exposure of the cells to hydro-
gen peroxide, which is related with TH production, led
to reduced levels of AUF1. Furthermore, the cells over-
expressing AUF1 were resistant to hydrogen peroxide-
induced senescence. However whether AUF1 protective
function against oxidative stress may be linked to thyr-
oid function and disorders remains to be elucidated
[82]. HuR was found to interact with the 3′UTR of the
HuR mRNA and elevated HuR translation by promoting
the nuclear export of HuR mRNA. The authors propose
that such a regulatory mechanism may be responsible
for the loss of HuR during replicative senescence [83].
Nagaoka et al. showed that AUF1 may be implicated
in mammary gland differentiation. It had been demon-
strated that stimulation with lactogenic hormone
decreased cytoplasmic, but increased nuclear AUF1
levels. Furthermore, depletion of AUF1 correlated with
elevated expression of b-casein and decreased levels of
c-myc mRNAs. Such a cytoplasmic-nuclear translocation
of AUF1 allowed the cells initiation of differentiation
followed by induction of milk production and inhibition
of proliferation [84].
Conclusions
The possibility of functional interactions between AUF1
and HuR, and thyroid related mRNAs presented in this
study is still speculative, but open new ways to investi-
gate the unrevealed mechanisms, far beyond the known
function of both proteins.
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